Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Immunomedics logo — company profile

Immunomedics

Founded 1982 United States United States 103 employees Post-IPO Equity Total: $802.00M Biopharma, Biotechnology +2

General Information

Company Name Immunomedics
Founded Year 1982
Location United States United States
Employees 103
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Immunomedics. To contact Immunomedics, visit immunomedics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Immunomedics compare?

A PDF of Immunomedics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Immunomedics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Immunomedics

Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with hard-to-treat cancers. Founded in 1982, the company operates in the Biopharma, Biotechnology, Health Care, and Health and Wellness industries with headquarters in the United States. The latest significant investment in Immunomedics was a $250.00M Post-IPO Equity investment on 04 December 2019. The details of the last investment's investors are not available at the moment. This company's innovative approach to cancer treatment and solid financial backing make it an intriguing prospect for potential investors in the healthcare and biotech sectors.

Business keywords: Immunomedics, Antibody-drug conjugate, Cancer treatment, Innovative technology, Biopharmaceutical, Medical innovation

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $250.00M -
04 Dec 2019
Post IPO Equity $317.00M -
01 Jun 2018
Convertible Note $80.00M -
01 Sep 2017
Post IPO Equity $125.00M -
01 May 2017
Post IPO Equity Undisclosed 1
New Enterprise Associates
New Enterprise Associates
01 Jan 2017
Post IPO Equity $30.00M -
08 May 2014

Immunomedics Alternatives & Competitors

View All Alternatives
Immunomedics vs
ADC Biotechnology
ADC Biotechnology

Accelerating solutions for developers to overcome conjugation challenges, making new ADC-based anti-...

Venture round
Biopharma, Biotechnology
Immunomedics vs
Emergence Therapeutics
Emergence Therapeutics Germany

Emergence Therapeutics creates effective immuno-therapeutics to target Nectin-4 and other cancers.

Series A
Biotechnology, Health Care
Immunomedics vs
ProfoundBio
ProfoundBio United States

An oncology biotherapeutics company

Series B
8 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Immunomedics

Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with hard-to-treat cancers.
Immunomedics was founded in 1982.
Immunomedics is headquartered in United States.
Immunomedics operates in Biopharma, Biotechnology, Health Care and Health and Wellness. Its work centres on Immunomedics, Antibody-drug conjugate, Cancer treatment and Innovative technology.
Immunomedics has approximately 103 employees.
Immunomedics has completed 6 funding rounds, raising a total of $802.00M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Immunomedics include ADC Biotechnology, Emergence Therapeutics, ProfoundBio, Tagworks Pharmaceuticals, Elevation Oncology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Immunomedics and ADC Biotechnology are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Immunomedics, https://bouncewatch.com/company/immunomedics, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes